In our previous work by Simon et al. [12], a pioneering study regarding the efficient loading of gold nanoparticles (GNPs) with selected FLT3 inhibitors, we showed that Pluronic-capped, Midostaurin (MDS)-conjugated GNPs might be promising anti-leukemic candidates with a high drug loading value of 80%, a drug release rate of 50% in simulated lysosomal conditions after 24 h, a clear reduction in cancer cell proliferation compared to control, and a superior anti-cancer effect compared to the free drug. Here, FLT3 is linked to cancer.